Non-dilutive funding first: why sequence changes what your round costs
For research-driven companies, what you prove with grant funding before raising materially changes the terms available. The reasoning and the trade-offs.
Two ways to answer the same question
An early-stage research company usually has one dominant unknown — whether the thing works at all, whether it can be manufactured, whether there is a regulatory path. An investor pricing that round is pricing that unknown.
There are two ways to resolve it. Sell equity and use the money to find out, or apply for non-dilutive funding and use that instead. The work is identical. The cost is not.
What the sequence is worth
Equity sold before a feasibility question is answered is sold at the price uncertainty commands. The same equity sold afterwards is priced against a de-risked asset.
Federal funding does not take equity at all. Every phase completed is a question an investor no longer has to take on faith, and the terms reflect it. For companies with a credible federal path, that sequencing is usually worth more than the grant money itself.
The trade-offs, honestly
It is not free. Federal cycles are slow — months from submission to decision, and a real funding gap between phases that has to be planned for rather than discovered. Applications consume founder time at exactly the stage founder time is scarcest. Grant-funded work is scoped to what was proposed, which is less flexible than equity.
For a company in a genuine race, the slower path can be the wrong one. That is a real judgement, not a formality.
When it does not apply
Not every business is fundable federally. If the work is primarily commercial development rather than research, if the sector does not map to an agency's mission, or if timing genuinely rules out a cycle, then the answer is to raise.
The point is not that non-dilutive funding is always right. It is that the sequence is a decision worth making deliberately, and it is frequently made by default.
Planning the arc
Where both routes apply, they should be planned together. What a Phase I is designed to demonstrate determines whether Phase II is a natural continuation, and both determine what an investor is being asked to underwrite afterwards.
Treating the grant application and the fundraise as separate exercises, run by different people at different times, is how companies end up having proved something no investor was asking about.
This is a description of how these rules and processes generally work, not legal, financial or tax advice. Regulations change and specific circumstances differ — confirm anything that matters with your own counsel or sponsored programmes office.